Amylin Pharmaceuticals and Biocon are to collaborate on the development of Amylin’s phybrid technology for the treatment of diabetes. Amylin will provide expertise in peptide hormone development and Biocon will utilise its expertise in recombinant microbial expression to manufacture the drug.